MedTrace Logo

Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction

NCT03394911 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2020-10-19

No results posted yet for this study

Summary

Healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth. Elevated mood eventually becomes accommodated after a few weeks. The pheromone contains volatile airborne sub-pheromones which cause aversive behavior (distrust, superstition, suspicion, arrogance, astonishment/stupidity, jealousy). Artificial jealousy can be avoided by patient isolation for 40 days until the pheromone "taste" wears off the saliva. The pheromone provided is odorless, colorless, and tasteless to the conscious brain.

Conditions

  • Opioid Addiction
  • Opioid Abuse, Continuous Use
  • Opioid Use
  • Opioid-Related Disorders
  • Paternal Pheromone Deficiency
  • Opioid Dependence
  • Opioid Abuse
  • Opioid-use Disorder
  • Opioid Intoxication
  • Opioid Abuse, Episodic

Interventions

BIOLOGICAL

250mg healthy adult male facial skin surface lipid liquid pheromone

Human Pheromone provided p.o. to tox-screen verified opioid drug addict

Sponsors & Collaborators

  • Tampa General Hospital

    collaborator OTHER

  • Otrimed Clinical Research

    collaborator OTHER

  • Bubba Nicholson

    lead INDUSTRY

Principal Investigators

  • Ross C Nicholson, BsIMGT · Nicholson Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2021-11-30
Completion
2021-11-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03394911 on ClinicalTrials.gov